The FDA approved dihydroergotamine (DHE) mesylate injection (Brekiya) to treat acute migraine (with or without aura) and cluster headaches in adults, Amneal Pharmaceuticals announced Thursday. The ...
The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ Brekiya (dihydroergotamine (DHE) mesylate) autoinjector for the treatment of acute migraine with or without aura and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback